{"id":"W2148264387","doi":"10.1200/jco.2007.14.3420","title":"Phase II Evaluation of Imatinib Mesylate in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Ottawa","funders":"National Cancer Institute","keywords":"Medicine; Imatinib mesylate; Internal medicine; Tolerability; Imatinib; Gynecologic oncology; Vascular endothelial growth factor; Platelet-derived growth factor receptor; Oncology; Ovarian carcinoma; Carcinoma; Gastroenterology; Pathology; Ovarian cancer; Cancer; Growth factor; Receptor; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001274947,0.0009887381,0.001143953,0.0002779955,0.0001846972,0.0005063969,0.0005090992,0.0009571585,0.002607865],"category_scores_gemma":[0.0007023608,0.0002834455,0.0007904186,0.0002432312,0.0004707167,0.0003379764,0.0002444352,0.00142098,0.0004662003],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005332797,"about_ca_system_score_gemma":0.0009015211,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004944635,"about_ca_topic_score_gemma":0.001385929,"domain_scores_codex":[0.999671,0.0001906358,0.00001606744,0.00004366955,0.00002655516,0.00005208802],"domain_scores_gemma":[0.9994606,0.00009100738,0.0001349366,0.00004452038,0.00002770049,0.0002411558],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6867251,0.05155427,0.02428273,0.001398621,0.002397254,0.0006772722,0.0004076743,0.003257002,0.06795097,0.0003152596,0.005144794,0.1558891],"study_design_scores_gemma":[0.6314983,0.3346679,0.02496201,0.0000481715,0.000567766,0.0004466982,0.00004794179,0.0009828031,0.003646884,0.0001293436,0.002981358,0.00002077703],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951589,0.002038946,0.0002565947,0.0002969094,0.00005094478,0.001040991,0.0004714672,0.00003429567,0.000651035],"genre_scores_gemma":[0.9918801,0.001587405,0.0009807786,0.0007808834,0.0001124215,0.001721263,0.001567559,0.00001548609,0.001354085],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002607865,"threshold_uncertainty_score":0.008724153,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3437575897750259,"score_gpt":0.5152730711735055,"score_spread":0.1715154813984796,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}